Does ACA meet expectations for pharmacies?
The passage of the Patient Protection and Affordable Care Act in 2010 (ACA) promised fundamental changes in the American health care environment.
Opinion
How big data will disrupt role of community pharmacy
Can retail pharmacies beat other players to patient intimacy? Many pharmacy retailers understand that big data can improve business operations, enabling intimate consumer engagement and thereby driving bigger baskets and more door turns, along with healthier customers and margins.
Drug chains play to their strengths
As the Christmas selling season begins, it’s becoming increasingly apparent that mass retailers are concerned about business. Not that they have nothing to offer their customers; rather, they have little to offer that’s exciting, new, different, compelling, or even mildly interesting.
Time is right for pharmacy to assert itself
The Republican wave that swept across the country in this month’s midterm elections transformed the political landscape and raised hopes, however fragile, that the gridlock that has come to characterize Washington in recent years might be alleviated, if not completely overcome.
Retail industry in need of more interaction
Mass market retailing, once the scene of an apparently ongoing string of meetings, conferences, exhibit shows and discussions, has morphed into an industry where such gatherings are disappointingly few and far between.
NACDS Foundation functions as a catalyst
A New Prescription for Health Care Improvement” examines a previously murky aspect of the problem: newly prescribed drugs
Other issues take precedence over selling
exactly. Rather, the issue is that retailing, just prior to the Christmas selling season, has become dangerously internalized — and socialized. The talk these days is all about individual companies and the issues that surround them. Perhaps more ominous, much of the discussion revolves around social
A look at the Harvoni/Sovaldi conundrum
Gilead Sciences and its breakthrough work in developing treatments for hepatitis C, the frequently devastating liver disease, have in recent months become the focal point of the debate about the cost and benefits of pharmaceutical products.
Helping consumers navigate the wild world of health apps
The Wild West never lacked for traveling salesmen pushing the newest elixir or snake oil to solve all your medical maladies.
For consumers, value, not price, is paramount factor
In a multipart series throughout 2014, our team is examining key product attributes and marketing tactics from two different perspectives: the retail buyer and the consumer/shopper. This objective picture of the two viewpoints should contribute to a product’s success at retail.
New opportunities created by ‘The Wellness Uprising’
Recently, Walmart announced it would open a dozen Walmart Care Clinics, primary care medical facilities, in stores in under-served communities.
Drug chains lead way in retail health care
The three most influential health care retailers in America are drug chains. They are, in no particular order, Walgreens, CVS Health and Rite Aid. In a sense, this is a surprise. Over the past several years, every major mass retailer in the U.S. has put an emphasis on health care.
Disruptive changes in store for pharma sector
The nation’s health care system is in upheaval, with, to borrow a phrase from William Wordsworth, “the meagre, stale, forbidding ways of custom” under siege.
CVS changes health care game at retail
In a year crammed with major news stories, cataclysmic personnel shifts and stunning new strategies and directions, the No. 1 retailing story of 2014 increasingly appears to be the CVS decision, announced early this year, to stop selling tobacco products in its 7,700 drug stores.
Business leaders gear up to drive change
October 1 is the first anniversary of the debut of the federal and state health care exchanges that allow Americans to assess insurance options and purchase coverage under the Affordable Care Act. Since then 7.3 million people have signed up, and another 4.
It’s time to build on Hatch-Waxman’s legacy
When President Ronald Reagan signed the Drug Price Competition and Patent Term Restoration Act 30 years ago, few could imagine how the law would transform the health care landscape.